Newron Pharmaceuticals S.p.A.

NWRN

IT0004147952

Pharmaceuticals

Market Closed - Swiss Exchange Other stock markets 11:31:59 2024-04-30 am EDT			5-day change	1st Jan Change
8.21 ^CHF	+7.46%		+14.35%	+65.86%

Apr. 30	Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	CI
Apr. 17	Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member	CI

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

April 16, 2024

Newron Pharmaceuticals S.p.A. announced that at the 2024 AGM held on April 17, 2024, the shareholders elected Margarita Chavez as independent Board member.

Latest news about Newron Pharmaceuticals S.p.A.

Newron Pharmaceuticals S.p.A. Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients	Apr. 30	CI
Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member	Apr. 16	CI
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 19	CI
Transcript : Newron Pharmaceuticals S.p.A., 2023 Earnings Call, Mar 19, 2024	Mar. 19
Newron Pharmaceuticals' FY23 Loss Narrows; Revenue Up	Mar. 19	MT
Newron Pharmaceuticals S.p.A. Announces Agreement with the European Investment Bank to Extend the Near-Term Tranche Repayment Dates of Its 2018 Financing Agreement	Mar. 15	CI
Newron Pharmaceuticals Secures Extension on Three Loan Repayments	Mar. 15	MT
Newron Pharmaceuticals Investor Subscribes for Nearly EUR6 Million Shares	Mar. 15	MT
Swiss Equities Edge Higher as Markets Continue to Weigh Rate Cut Outlook	Jan. 04	MT
Transcript : Newron Pharmaceuticals S.p.A. - Special Call	Jan. 04
Newron Reports Exceptional One-Year Results of Study 014/15 with Evenamide in Treatment-Resistant Schizophrenia	Jan. 04	CI
Newron Pharmaceuticals' Schizophrenia Drug Lowers Disease Severity in Clinical Studies	Jan. 04	MT
Swiss Equities Rally as Economic Barometer Hits Eight-month High at Year-end	Dec. 29	MT
Newron Pharmaceuticals Completes Enrolment of Schizophrenia Patients for Evenamide Clinical Study	Dec. 29	MT
Newron Pharmaceuticals S.p.A. Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A with Evenamide	Dec. 29	CI
Newron Pharmaceuticals S.P.A. Presents New Data from Study 014/015 Evaluating Its Investigational Drug Evenamide for the Management of Treatment Resistant Schizophrenia	23-10-09	CI
Newron Pharmaceuticals S.p.A. Appoints Margarita Chavez as Board Advisor	23-10-02	CI
Newron Pharmaceuticals S.p.A.(SWX:NWRN) added to S&P Global BMI Index	23-09-18	CI
Newron Pharmaceuticals Net Loss Narrows in H1; Revenue Grows	23-08-04	MT
Newron Pharmaceuticals S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-03	CI
Newron Pharmaceuticals S.P.A. Announces Marco Caremi, Executive Vice President Business Development Will Leave the Company as Per End of June 2023	23-05-02	CI
Newron Pharmaceuticals Promotes Finance VP to CFO	23-05-02	MT
Newron Pharmaceuticals S.p.A. Presents Six-Month Interim Data from the First 100 Patients Randomized in Study 014/015 At the 31St European Congress of Psychiatry	23-03-28	CI
Newron Pharmaceuticals S.p.A. Reports Compelling Topline Results from All Patients in Study 014, its Phase II Clinical Trial Evaluating Evenamide as Add-On Therapy for Treatment-Resistant Schizophrenia	23-03-20	CI
Newron Pharmaceuticals' Schizophrenia Drug Shows Significant Improvement in Efficacy	23-03-20	MT

Chart Newron Pharmaceuticals S.p.A.

Duration

Period

More charts

Newron Pharmaceuticals SpA is an Italy-based clinical-stage biopharmaceutical company. It focuses on the discovery and development of pharmaceutical products. The Company is engaged in discovering and developing new therapies for diseases of the Central Nervous System (CNS) and pain. The Company undertakes phase III trials with safinamide molecule for the treatment of patients with Parkinsonâs disease. Newron Pharmaceuticals SpA develops ralfinamide, a molecule for the treatment of neuropathic pain. Its additional projects, such as HF0220 for neuroprotection, NW-3509 for the treatment of schizophrenia, as well as pruvanserin and sarizotan for treatment of CNS diseases, are at various stages of preclinical and clinical development.

Sector

Pharmaceuticals

Calendar

2024-05-12 - German Spring Conference

More about the company

Income Statement Evolution

More financial data

Ratings for Newron Pharmaceuticals S.p.A.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.376 EUR

Average target price

14.84 EUR

Spread / Average Target

+77.13%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
NEWRON PHARMACEUTICALS S.P.A.	+65.86%	167M
CSL LIMITED	-4.24%	86.85B
SAMSUNG BIOLOGICS CO.,LTD.	+2.76%	40.16B
BIOGEN INC.	-16.79%	31.28B
UCB	+57.86%	25.27B
BIOMARIN PHARMACEUTICAL INC.	-14.19%	15.33B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.12%	11.96B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-42.56%	11.61B
SWEDISH ORPHAN BIOVITRUM AB	+6.89%	8.83B
INNOVENT BIOLOGICS, INC.	-10.53%	7.94B

Biopharmaceuticals

Newron Pharmaceuticals S.p.A.

Equities

NWRN

IT0004147952

Pharmaceuticals

Newron Pharmaceuticals Appoints Margarita Chavez as Independent Board Member

Latest news about Newron Pharmaceuticals S.p.A.

Chart Newron Pharmaceuticals S.p.A.

Company Profile

Income Statement Evolution

Ratings for Newron Pharmaceuticals S.p.A.

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Biopharmaceuticals